Harper Hubbeling, MD

Radiation Oncology
Accepting new patients
Sees patients age 18 and up
Penn Radiation Oncology Perelman - 2nd Floor
Headshot of Harper Hubbeling, MD
Penn Medicine Provider

About me

  • Assistant Professor of Radiation Oncology at the Hospital of the University of Pennsylvania

My education and training

  • Medical School: Harvard Medical School
  • Residency: Memorial Sloan-Kettering Cancer Center

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Chester County Hospital: Has privileges to treat patients in the hospital.
Dr. Hubbeling is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Jonathan Baron, Gurbani Singh, Francesca Costabile, Carlos Chavez Perez, Miguel Perez-Guillermo Cuev, Emeline Chong, Colin Thomas, Jordan Carter, Sunita Nasta, Daniel Landsburg, Nektarios Kostopoulos, Stefan Barta, Jakub Svoboda, Stephen Schuster, Elise Chong, John Plastaras, Michael LaRiviere, Andrea Facciabene, Harper Hubbeling Low-Dose Hypofractionated Bridging Radiation (4Gy x 2 Fractions) Prior to CAR T-Cell Therapy for Relapsed/Refractory DLBCL , ASTRO 2026 annual meeting: 2026


Jiang C, Hoover T, Baron J, Han X, Li B, Gao Y, Kim M, Hubbeling H, Chong EA, Carter J, Svoboda J, Schuster SJ, Landsburg DJ, Nasta SD, Plastaras J, LaRiviere M Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma , Int J Part Ther: 2026


Baron J, Chelius M, Cohen L, Perez CC, Riina M, Ramesh S, Tierney A, Elghawy O, Hossain NM, Rook A, Villasenor-Park J, Samimi S, Kim E, Hubbeling H, Plastaras JP, Barta SK, LaRiviere M Standard Versus Hypofractionated Low-Dose Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma: A Single-Institution Retrospective Analysis , Pract Radiat Oncol: 2026


Linkowski L, Messing I, Berger M, Hollawell C, Friedes C, Alexander D, Wang X, Desai AS, Phillips RE, O'Rourke DM, Amankulor NM, Jackson C, Hubbeling H, Kurtz G, Bagley SJ, Bradley JD, Mohan S, Alonso-Basanta M, Lebow ES. Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series , J Radiat Oncol Biol Phys: 2026


Jonathan Baron, Monica Chelius, Gurbani Singh, Melanie Berger, Emeline Chong, Colin Thomas, Jordan Carter, Sunita Nasta, Daniel Landsburg, Stefan Barta, Jakub Svoboda, Stephen Schuster, Nikhil Yegya-Raman, Michael LaRiviere, John Plastaras, Elise Chong, Harper Hubbeling Safe Integration of Radiation Therapy with Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas , ASTRO 2026 Annual Meeting: 2026


Jonathan A Baron, Monica Chelius, MD; Gurbani Singh, MD; Michael D. Schad, MD; Melanie Berger, MD; Emeline R. Chong; Colin J. Thomas, MD; Jordan S. Carter, MD; Michael R. Cook, MD; Sunita D. Nasta, MD; Daniel J. Landsburg, MD; Stefan K. Barta, MD; Jakub Svoboda, MD; Stephen J. Schuster, MD; Nikhil Yegya-Raman, MD; Michael J. LaRiviere, MD; John P. Plastaras, MD, PhD; Elise A. Chong, MD; Harper Hubbeling, MD Safe Integration of Radiation Therapy with Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas , Clinical Lymphoma, Myeloma and Leukemia: 2026


Friedes C, Berger M, Linkowski L, Hollawell C, Hubbeling H, Alexander D, Kurtz G, Lustig RA, Dorsey JF, Desai AS, Phillips RE, Brem S, Davatzikos C, Nasrallah M, O'Rourke DM, Jackson C, Amankulor NM, Alonso-Basanta M, Mohan S, Bagley SJ, Lebow ES Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort study , Neurooncol: 2026


Patel H, Hubbeling H, Yu K, Carpenter M, LaRiviere MJ, Plastaras JP, Cohen AD, Kapur S, Vogl DT, Waxman AJ, Stadtmauer EA, Garfall AL, Susanibar-Adaniya S Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma , Blood Adv: 2026


Baron JA, Cohen L, Chelius M, Messing I, Mallon J, Tierney A, Elghawy O, Hossain N, Rook A, Villasenor-Park J, Samimi S, Kim E, Hubbeling H, Plastaras JP, Barta SK, LaRiviere M Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma , Clin Lymphoma Myeloma Leuk: 2026


Thomas CJ, Myers CS, Chung J, Landsburg D, Nasta SD, Svoboda J, Chong EA, Schuster SJ, Carter J, Cook M, Tomasulo E, Elghawy O, LaRiviere M, Hubbeling H, Plastaras JP, Rook AH, Villasenor-Park J, Ruella M, Kim E, Barta SK Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden , Blood Neoplasia: 2026